The researchers developed an EPHB4-CAR-T cell (product name AP8901) that can specifically recognize and kill malignant tumor cells expressing the EPHB4 receptor by modifying ephrin B2, the natural ligand of the EPHB4 receptor (Figure 1). This evidence concerns the gene EFNB2 and neoplasm.